Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-12T01:53:37.911Z Has data issue: false hasContentIssue false

166 Radiation Therapy and IRreversible Electroporation (RTIRE) for Intermediate Risk Prostate Cancer

Published online by Cambridge University Press:  03 April 2024

Timothy McClure
Affiliation:
Weill Cornell Medicine
Francesca Khani
Affiliation:
Department of Pathology, New York Presbyterian/Weill Cornell Medicine, New York, NY, USA
Brian Robinson
Affiliation:
Department of Pathology, New York Presbyterian/Weill Cornell Medicine, New York, NY, USA
Ariel E Marciscano
Affiliation:
Department of Radiation Oncology, New York Presbyterian/Weill Cornell Medicine, New York, NY, USA
Christopher Barbieri
Affiliation:
Department of Urology, New York Presbyterian/Weill Cornell Medicine, New York, NY, USA
Joseph Osborne
Affiliation:
Department of Molecular Imaging and Therapeutics, New York Presbyterian/Weill Cornell Medicine, New York, NY, USA
Himanshu Nagar
Affiliation:
Department of Radiation Oncology, New York Presbyterian/Weill Cornell Medicine, New York, NY, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

OBJECTIVES/GOALS: Prostate cancer treatment is associated with significant genitourinary side effects. There is a critical need for treatment with decreased morbidity. We report the development of a novel treatment paradigm combining irreversible electroporation and lower dose radiation to provide prostate cancer patients with a less morbid treatment. METHODS/STUDY POPULATION: Intermediate risk prostate cancer patients will undergo focal irreversible electroporation followed by low dose, whole gland radiation therapy. The primary endpoint is freedom from clinically significant cancer on biopsy at 12-month follow up. Secondary endpoints include safety profile, oncologic efficacy, effectiveness of RT and need for secondary treatment. This trial (NCT05345444) and currently actively recruiting patients after initial feasibility trial. Sample size is calculated to detect an increase in the proportion of patients who are cancer free at 1-year, from 0.80 to 0.95. An exact binomial test with a 10% one-sided significance level will have 94.3% power to detect the difference between the null and alternative hypothesis when the sample size is 42. RESULTS/ANTICIPATED RESULTS: This is a clinical trial in progress. DISCUSSION/SIGNIFICANCE: Combined irreversible electroporation (IRE) and a lower dose radiotherapy (RTIRE) may provide prostate cancer patients a treatment with minimal side effects.

Type
Evaluation
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2024. The Association for Clinical and Translational Science